Biochemical bone turnover markers are useful tools to assess changes in bone metabolism in marmosets

Journal of Bone and Mineral Metabolism

Volumn 22, Issue 3, 2004, Pages 192-197

  Angeliewa, Anna ^a,b   Budde, Michael ^a   Schlachter, Manfred ^a   Hoyle, Nicholas R ^c   Bauss, Frieder ^c,d  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biochemical markers of bone turnover; Bone formation; Bone resorption; Ibandronate; Marmosets; Metabolic bone diseases; Osteoporosis

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; IBANDRONIC ACID; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BONE METABOLISM; BONE TURNOVER; CALCIUM URINE LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSS LINKING; FEMALE; MALE; MARMOSET; METABOLIC BONE DISEASE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SPECIES DIFFERENTIATION;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; CALLITHRIX; FEMALE; MALE; MULTIVARIATE ANALYSIS; VASECTOMY;

EID: 2442686422     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-003-0469-8     Document Type: Article

References (33)

1. Takahashi N, Suda S, Shinki Z, Horiuchi N, Shiina Y, Tanioka Y, Koizumi H, Suda T (1985) The mechanism of end-organ resistance to 1α,25 dihydroxycholecalciferol in the common marmoset. Biochem J 227:555-563
2. Suda T, Takahashi N, Shinki T, Yamaguchi A, Tanioka Y (1986) The common marmoset as an animal model for vitamin D-dependent rickets, type II. Adv Exp Med Biol 196:423-435
3. Colman RJ, Salzman W, Abbott DH, Kemnitz JW, Binkley N (1997) Absence of estrogen depletion bone loss in female common marmosets. J Bone Miner Res 12:S342
4. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2000) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592
5. Fleisch HA (1997) Bisphosphonates in Bone Disease, from the Laboratory to the Patient. Parthenon Publishing, NewYork
6. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011
7. Bauss F (1997) Ibandronate in malignant bone diseases and osteoporosis - preclinical results. Onkologie 20:204-208
8. Bauss F, Wagner M, Hothorn LH (2002) The total administered dose of ibandronate determines its effect on bone mass and architecture in ovariectomized aged rats. J Rheumatol 29:990-998
9. Monier-Faugere M-C, Friedler RM, Bauss F, Malluche HH (1993) A new bisphosphonate, BM 21.0955 prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 8:1345-1355
10. Monier-Faugere M-C, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH (1999) Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778
11. Smith SY, Recker R, Hannan M, Bauss F (1999) Effects of ibandronate treatment on bone mass, architecture and strength in the ovariectomized cynomolgus monkey. J Bone Miner Res 14(Suppl 1):S402
12. Juraschek M, Seibel MJ, Woitge HW, Krempien B, Bauss F (2000) Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of PTHrP-mediated tumor osteolysis. Bone 26:475-483
13. Arakawa N, Kim M, Otsuka M (1992) An improved high-performance liquid chromatographic assay for the determination of pyridinoline in connective tissues. J Nutr Sci Vit 38:375-380
14. Black D, Duncan A, Robins SP (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197-203
15. Robins SP, Duncan A, Wilson N, Evans BJ (1996) Standardization of pyridinium crosslinks, pyridinoliine and desoxypyridinoline, for use of biochemical markers of collagen degradation. Clin Chem 42:1621-1626
16. Hoyle NR, Kyriatsoulis A, Kraus W, Naser W (1988) Automated assay of bone status: performance of three new electrochemiluminescent assays for C-telopeptide, osteocalcin and PTH. Bone 23(Suppl):F430
17. Helger R, Rindfrey H, Hilgenfeldt J (1974) Eine Methode zur direkten Bestimmung des Creatinins im Serum und Urin ohne Enteiweissung nach einer spezifischen modifizierten Jaffe-Reaktion. Z Klin Chem Klin Biochem 12:344-349
18. Aitchison J Jr, Brown JAC (1957) The Lognormal Distribution. Cambridge University Press, New York, p 176
19. Frison L, Pocock SJ (1992) Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Statist Med 11:1685-1704
20. Schlosser K, Scigalla P (1997) Biochemical markers as surrogates in clinical trials with metastatic bone disease and osteoporosis. Scand J Clin Lab Invest 57(Suppl 227):21-22
21. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307
22. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871-1878
23. Reid IR, Brown JP, Burkhardt P, Horrowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer J-P, Kaufmann J-M, Jaeger P, Body J-J, Meunier PJ (2002) Intravenous zoledronic acid in post-menopausal women with low bone mineral density. N Engl J Med 346:653-661
24. Christgau S, Rosenquist C, Alexandersen P, Bjarnson NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C (1998) Clinical evaluation of the Serum CrossLaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products from type I collagen C-telopetides. Clin Chem 44:2290-2300
25. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Quist P, Christiansen C (1998) Serum CrossLaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopetides of type I collagen. Clin Chem 44:2281-2289
26. Gundberg CJ, Markovitz ME, Mizruchi M, Rosen JF (1985) Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 60:736-739
27. Nielsen HK, Brixen K, Bouillon R, Mosekilde L (1990) Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Endocrinol Metab 70:1431-1437
28. Hotchkiss CE, Brommage R (2000) Changes in bone turnover during the menstrual cycle in cynomolgus monkeys. Calcif Tissue Int 66:224-228
29. Fleisch H (1996) The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. Osteoporos Int 6:166-170
30. Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J (1998) Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13:1775-1782
31. Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694-702
32. Tohme JF, Seibel MJ, Silverberg SJ, Robins SP, Bilezikian JP (1991) Biochemical markers of bone metabolism. Z Rheumatol 50:133-141
33. Cahoon S, Boden SD, Gould KG, Vailas AC (1996) Noninvasive markers of bone metabolism in the rhesus monkey: normal effects of age and gender. J Med Primatol 25:333-338